Patents Assigned to Heron Therapeutics, Inc.
-
Patent number: 9974742Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: February 1, 2016Date of Patent: May 22, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Patent number: 9913910Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: September 19, 2016Date of Patent: March 13, 2018Assignee: Heron Therapeutics, Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller -
Patent number: 9913909Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: September 19, 2016Date of Patent: March 13, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
-
Patent number: 9808465Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: September 18, 2015Date of Patent: November 7, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 9801945Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: October 21, 2016Date of Patent: October 31, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 9744163Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: March 13, 2014Date of Patent: August 29, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
-
Patent number: 9694079Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: September 9, 2016Date of Patent: July 4, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 9592227Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: March 13, 2014Date of Patent: March 14, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
-
Patent number: 9561229Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: March 28, 2016Date of Patent: February 7, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 9446036Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: March 14, 2014Date of Patent: September 20, 2016Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
-
Publication number: 20150359897Abstract: A method for treating chemotherapy-induced nausea and vomiting in individuals undergoing chemotherapy and previously treated with, and whom failed to respond to, a 5-HT3 antagonist other than granisetron is described. Individuals who fail to respond to, for example, palonosetron, as evidenced by an inadequate prevention or attenuation of acute or delayed chemotherapy-induced nausea and vomiting, are treated with a semi-solid drug delivery vehicle that provides a sustained release of granisetron.Type: ApplicationFiled: February 4, 2014Publication date: December 17, 2015Applicant: HERON THERAPEUTICS, INC.Inventors: John Barr, Erin O'Boyle, John B. Whelan
-
Publication number: 20140371187Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: ApplicationFiled: April 15, 2014Publication date: December 18, 2014Applicant: Heron Therapeutics, Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller
-
Publication number: 20140323517Abstract: A method for administering a polymeric-based delivery system to a subject is described. The method comprises contacting a housing comprising a polymer-based delivery system with a heat-generating component for a period of time; and injecting the delivery system into the subject.Type: ApplicationFiled: April 29, 2014Publication date: October 30, 2014Applicant: Heron Therapeutics, Inc.Inventor: John Whelan
-
Publication number: 20140296282Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: ApplicationFiled: March 14, 2014Publication date: October 2, 2014Applicant: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
-
Publication number: 20140275145Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
-
Publication number: 20140275046Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
-
Patent number: 8715710Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: July 18, 2012Date of Patent: May 6, 2014Assignee: Heron Therapeutics, Inc.Inventors: Steven Y. Ng, Hui Rong Shen, Jorge Heller